PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research

Abstract 3145: Pharmacologic inhibition of SREBP-driven lipogenesis suppresses metastatic progression in prostate cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

PPPrashanth Reddy ParupathiSDSirisha DevarakondaEFEkniel Francois

Discussion

Loading...

Member takes

Overview

This analysis reveals that targeting SREBPs in prostate cancer can reduce invasiveness, indicating a potential therapeutic approach.

Key Points

  • The study aims to explore how SREBP-driven lipid metabolism contributes to the progression of prostate cancer and assess the effects of fatostatin as an inhibitor.
  • Analyzed publicly available gene expression datasets of prostate cancer and normal tissue.
  • Evaluated the effect of fatostatin on viability, proliferation, and invasion in various prostate cancer cell lines.
  • Utilized immunoblotting to measure SREBP expression and pathway analysis through RNA-Seq.
  • Increased SREBP expression was observed in metastatic prostate tumors compared to primary tumors.
  • Fatostatin significantly inhibited cell viability and migration in more invasive PCa cell lines.
  • Pathways related to epithelial-to-mesenchymal transition (EMT) and mTORC1 were downregulated after fatostatin treatment.

Cite This Study

Parupathi et al. (2026) studied this question.

synapsesocial.com/papers/69d1fcc0a79560c99a0a260bhttps://doi.org/10.1158/1538-7445.am2026-3145
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 3144: Targeting AR-SREBP crosstalk in prostate adenocarcinoma2026
  2. 2Abstract 2077: Exploring the multifaceted efficacy of de novo lipogenesis inhibitor in cancer therapy2024
  3. 3Abstract 4742: Investigating the crosstalk between metabolic reprogramming and epigenetic modifications in bone metastatic prostate cancer2026
  4. 4Reprogrammed Lipid Metabolism-Associated Therapeutic Vulnerabilities in Prostate Cancer2025 · 15 citations
  5. 5Abstract 3064: Unmasking the deadly tango: PKA and lipid genes in prostate cancer's bone invasion2024